Formally known as Retatrutide, GLP-3 is a novel investigational peptide developed for the treatment of obesity, type 2 diabetes, and other metabolic disorders. This drug is a triple-hormone-receptor agonist, targeting the GLP-1 (Glucagon-like peptide-1), GIP (Gastric inhibitory polypeptide), and GCGR (Glucagon receptor), which play crucial roles in metabolic regulation and appetite control.
Clinical trials have shown that GLP-3 can achieve up to a 17.5% mean weight reduction at 24 weeks and 24.2% at 48 weeks. The phase 2 dosing titration schedule for GLP-3, as part of its clinical development for weight loss and other conditions, typically involves a gradual increase in dosage over a period to minimize side effects and allow the body to adjust to the medication.
- Potential Weight Loss with Minimal Muscle Loss
- Reduce Fat Mass
- Decrease Blood Glucose and Insulin Levels
- Increase Energy Expenditure
- Lipid Oxidation
Researchers have often combined GLP-3 with Ipamorelin, BPC-157, AOD-9604 and even alternating with Tirzepatide.
Vial contains lyophilized product. Reconstitution solution of choice must be added before use.
Reviews
There are no reviews yet.